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Objective: The Endurant endograft (Medtronic Inc, Minneapolis, Minn) is a new-generation device speciﬁcally developed
to perform well in complex abdominal aortic aneurysm anatomy. Previous reports on the 1- and 2-year results of
endovascular aneurysm repair (EVAR) with the Endurant endograft showed excellent outcome, including prevention of
migration and type I endoleaks, but occurrence and outcome of post-EVAR occlusion have not been determined in a large
multicenter patient cohort with midterm follow-up, which is the objective of this study.
Methods: Data of consecutive patients treated with the Endurant from December 2007 to April 2012 in three Dutch
tertiary vascular referral hospitals were prospectively gathered and retrospectively analyzed. Follow-up consisted of
regular ofﬁce visits, computed tomography angiography at 1 and 12 months after EVAR, and subsequently, duplex
ultrasound imaging or computed tomography angiography at regular intervals. Patients with ruptured aneurysms or with
earlier abdominal aortic surgery were excluded. The incidence and clinical outcome of endograft occlusions were analyzed.
An expert review board assessed all cases in the search for possible causes of occlusion.
Results: Included were 496 patients (87.7% male), who were a median age of 74 years (range, 68-78 years). Median
follow-up was 1.7 years (range, 0-4.6 years). Twenty graft occlusions (4.0%) occurred during follow-up. Median time
between primary EVAR and detection of the occlusion was 1 month, with 55% occurring#60 postoperative days and 90%
#1 year. No association was found between occlusion and sex (P[ .28), age (P[ .96), or use of an aortouniiliac device
(P [ .66). Technical error was the considered cause of the occlusion in 12 patients (60%). The estimated freedom from
occlusion was 98.4% at 30 days, 95.7% at 1 year, and 95.3% at 3 years. Presenting symptoms of occlusion were acute limb
ischemia in 50%. Treatment was surgical (75%) or percutaneous (25%). Successful revascularization was achieved in 17 of
20 patients, but reocclusions occurred in ﬁve, resulting in a transfemoral amputation in one patient. Occlusion-related
mortality was 0.6% (3 of 496).
Conclusions: At a median follow-up of 1.7 years, Endurant endograft occlusion occurred in 4.0% of 496 patients. Most
occlusions occurred #2 months after EVAR, and rarely after 1 year. A technical justiﬁcation for occlusion could be found
for 60% of patients. A more liberal intraoperative and early postoperative (re)intervention strategy may reduce the
occlusion rates and improve outcome. (J Vasc Surg 2013;57:1246-54.)Aortic endograft occlusion is a known complication
after endovascular aneurysm repair (EVAR),1-6 with a re-
ported incidence of 0% to 7.2%, with signiﬁcant variability
(Table I).2,4-25 Although most of the newer-generation
endografts have been associated with lower incidences
of graft occlusion compared with ﬁrst-generation endog-
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6of secondary interventions and rehospitalization after
EVAR.13,26,27
The Endurant stent graft (Medtronic Inc, Minneapolis,
Minn), one of the newest-generation endovascular devices,
was speciﬁcally developed to perform well in complex
abdominal aortic aneurysm (AAA) anatomy. However,
treatment of more complex AAA anatomies may result in
higher rates of complications, including stent graft occlu-
sion. Previous reports on the 1-year and 2-year results of
the Endurant endograft showed excellent outcome,
including prevention of migration and type IA endo-
leaks.21-24 However, the occurrence and outcome of occlu-
sions after EVAR have not yet been determined in a large
multicenter patient cohort with midterm follow-up, which
is the objective of this study.
METHODS
Data of all consecutive patients treatedwith anEndurant
endograft between December 2007 and April 2012 in
three Dutch tertiary vascular referral hospitals (University
Medical Center, Utrecht; Erasmus University Medical
Center, Rotterdam; andSt. AntoniusHospital,Nieuwegein)
were prospectively gathered and retrospectively reviewed.
Table I. Reported rates of limb thrombosis in literature
Study (ﬁrst author) Year No.
Endovascular
devices used Follow-up duration
Incidence of
occlusion (%)
Occlusion-related
mortality (%)
Carroccio2 2002 351 Mixed 20 months 3.7 0
Erzurum4 2004 823 Mixed 24.2 months 2.7 0.12
Cochennec5 2007 460 Mixed 23 months 7.2 3
Maleux6 2008 288 Mixed 39 months 3.1 0
EVAR 17 2010 624 Mixed 6 years 3.2 Not stated
EVAR 28 2010 229 Mixed 3.1 years 2.2 Not stated
DREAM9 2010 178 Mixed 6.4 years 6.7a Not stated
Van Marrewijk (EUROSTAR)10 2005 6787 Mixed 21 months 5 Not stated
Mehta, et al 11 2010 1768 Mixed 34 months 1.4 0.05
Karthikesalingam12 2010 553 Mixed 31 months 1.1 Not stated
Conrad13 2009 832 Mixed 35 months 2.9 0
Abbruzzese14 2008 565 Mixed 30 months 6b 0.35
Bos15 2009 92 Excluderc 36 months 0 0
Maleux16 2012 121 Excluder 4.05 years 1.6 Not stated
Bastos Gonçalves17 2012 144 Excluder 5 years 1.4 0
Mertens18 2011 143 Zenithd 66 months 5.6 Not stated
Sivamurthy19 2006 248 Zenith 24 months 5.2 0
Jean-Baptiste20 2009 447 Zenith 24 months 1.8 0
Torsello21 2010 45 Endurante 30 days 2.2 0
Troisi22 2010 156 Endurant 9 months 1.9 0
Van Keulen23 2011 100 Endurant 1 year 3.0 1
Rouwet24 2011 80 Endurant 1 year 1.3 0
Stokmans25 2012 1151 Endurant 30 days 2.0 Not stated
Current study 2012 496 Endurant 1.7 years 4.0 0.6
DREAM, Dutch Randomised Endovascular Aneurysm Management; EUROSTAR, European Collaborators on Stent-Graft Techniques for Aortic Aneurysm
Repair; EVAR 1, Comparison of Endovascular Aneurysm Repair with Open Repair in Patients with Abdominal Aortic Aneurysm; EVAR 2, United Kingdom
Endovascular Aneurysm Repair 2.
aIncludes all thrombo-occlusive complications.
bIntervention for thrombosis or stenosis.
cW. L. Gore and Assoc, Flagstaff, Ariz.
dCook, Bloomington, Ind.
eMedtronic, Minneapolis, Minn.
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AAA or aneurysm of the common iliac artery, or both. The
study excluded patients with ruptured AAAs or patients
who had previously undergone abdominal surgery.
EVAR at the three institutions is performed by board-
certiﬁed vascular surgeons and interventional radiologists,
who perform at least 50 EVAR procedures yearly.
Follow-up assessment. Follow-up consists of regular
ofﬁce visits at 1 and 12 months and yearly thereafter.
Computed tomography angiography (CTA) is routinely
performed #30 days after the index procedure and at 1
year, and subsequently, the choice of imaging modality is
individualized (eg, duplex ultrasound [DUS] imaging or
CTA). Follow-up duration was calculated until the day of
the last imaging examination performed to ensure that the
study also included asymptomatic occlusions.
The study group included all patients with endograft
occlusion on imaging examinations. Early occlusion was
deﬁned as occurring #60 days of the index procedure,
and delayed occlusion was deﬁned as occurring at a later
stage. CTAs or DUS images of asymptomatic patients
were not evaluated for the presence of nonhemodynami-
cally signiﬁcant stenosis, but we did identify all patients
who were treated for an asymptomatic preocclusive limb
lesion.Stent graft occlusions were identiﬁed during the post-
operative hospital stay after the primary EVAR proce-
dure, at ofﬁce visits during follow-up, or at emergency
department visits when the onset of symptoms was acute.
All patients included in the study group presented with
symptoms, which were classiﬁed according to Rutherford
et al.28 Presence of graft occlusion was conﬁrmed by
CTA, angiography, or magnetic resonance angiography
(MRA; Fig 1). The decision whether to treat an occlu-
sion and the type of intervention were at the discretion
of the treating vascular team. Presenting symptoms,
treatment, and outcome after treatment of patients with
a graft occlusion were recorded according to the Re-
porting Standards for Endovascular Aortic Aneurysm
Repair.29
A review board evaluated all imaging studies and inter-
ventional details of the patients included in the study group
during a consensus meeting. The review board included
vascular surgeons and interventional radiologists from the
study hospitals and three interventionists from unrelated
hospitals, not involved in any aspects of the study. All
review board members were very experienced in endovas-
cular aortic procedures. The probable causes of occlusion
in each individual case were discussed, and a conclusion
was reached by consensus.
Table II. Patient and operative characteristics
Variable No. (%) or median (IQR)
Patients 496
Male 435 (87.7)
Age, years 74 (68-78)
Aortouniiliac stent raft 38 (7.7)
Graft limbs at risk 954
IQR, Interquartile range.
Fig 1. Endograft occlusion is conﬁrmed by magnetic resonance
angiography (MRA).
Table III. Early and midterm outcome
Variable
No. (%)
or median (IQR)
Patients 496
30-day outcome
Overall 30-day mortality 4 (0.8)
30-day EVAR-related mortality 1 (0.2)
Patients with occlusion 7 (1.4)
30-day occlusion-related mortality 1 (0.2)
Midterm outcome
Follow-up, years 1.7 (0-4.6)
All-cause mortality 65 (13.1)
Overall EVAR-related mortality 6 (1.2)
Patients with occlusion 20 (4.0)
Occlusion-related mortality 3 (0.6)
EVAR, Endovascular aneurysm repair; IQR, interquartile range.
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counts and percentages and continuous variables as
means 6 standard deviation or medians (interquartile
range), according to the normality in distribution. Associa-
tion between early and delayed occlusion and sex, type of
endograft (aortouniiliac [AUI] or bifurcated), and treating
hospital was tested using logistic regression and Cox regres-
sion c2 tests, respectively. Association with age was tested
using the nonparametric Mann-Whitney U test. Kaplan-
Meier estimates for freedom from occlusion were obtained
for the overall population. Differences were considered
signiﬁcant at P< .05. Statistical analysis was performed with
SPSS 20.0 software (SPSS Inc, Chicago, Ill).
RESULTS
From December 2007 to April 2012, 631 patients with
an aneurysm of the infrarenal abdominal aorta or common
iliac artery, or both, were treated with an Endurant stent
graft. The study excluded 95 patients who were treated
for a ruptured aneurysm and 40 patients with earlier abdom-
inal aortic surgery, resulting in 496 patients (435 men
[87.7%]) included in this study. Median age at time of
primary EVAR was 74 years (range, 68-78 years; Table II).
Details of the primary EVAR procedure. An AUI
stent graft was implanted in 38 patients (7.7%), and a bifur-
cated device was used in 458 (92.3%), yielding 954 graft
limbs at risk for occlusion. No patients had signs of (immi-
nent) endograft occlusion at the end of the initial proce-
dure, which was checked with a completion angiogram.Outcome at 30 days. All-cause 30-day mortality was
0.8% (n ¼ 4; Table III). Thirty-day occlusion-related
mortality was 0.2% (n ¼ 1). This patient died of ischemic
complications after unsuccessful embolectomy of an
occluded graft limb that developed 1 day postoperatively in
the presence of pre-existent severe atherosclerosis and
a previous bilateral above-knee amputation. All other
patients died of nonsurgical complications.
Midterm results. Median follow-up was 1.7 years
(range, 0-4.6 years). Five patients were lost to follow-up.
All-cause mortality during follow-up was 13.1% (n ¼ 65),
with aneurysm-related mortality in six (1.2%). No patients
died of AAA rupture. Three patients (0.6%) died of
complications resulting from stent graft infection.
Endograft occlusions. During follow-up, there were
20 endograft occlusions (4.0%). Mortality was occlusion-
related in three patients (0.6%). These patients died of
ischemic complications after unsuccessful revascularization
(n ¼ 1), reperfusion syndrome (n ¼ 1), and during open
conversion of an inﬂammatory aneurysm with signiﬁcant
retroperitoneal ﬁbrosis, due to uncontrollable bleeding from
aortic laceration at the site of cross-clamping (n ¼ 1). No
association could be found between occlusion and sex
(P¼ .28), age (P¼ .96), or use of an AUI device (P¼ .66).
Overall, the treating hospital had no signiﬁcant association
with the chance of occlusion (P ¼ .08), but looking speciﬁ-
cally at early occlusions, a difference in hospitals could be
found (odds ratio, 3.08; 95% conﬁdence interval, 1.13-8.39;
P¼ .028). The estimated freedom fromocclusionwas 98.4%
at 30 days, 95.7% at 1 year, and 95.3% at 3 years (Fig 2).
Fig 2. Kaplan-Meier curve shows the rate of freedom from
occlusion at 4 years after endovascular aneurysm repair (EVAR).
SD, Standard deviation.
Table IV. Symptoms
Variable No. (%)
Occlusions 20 (4.0)
Asymptomatic occlusions 0 (0)
Acute symptoms
Rutherford classa
IIa 3 (15)
IIb 7 (35)
Nonacute symptoms
Rutherford class I-IIIb 10 (50)
aAcute ischemia.
bChronic limb ischemia.
Fig 3. Left, Tortuous right external iliac artery in a patient with
both infrarenal aortic aneurysm and right common iliac artery
aneurysm. Right, The right limb of the Endurant endograft has
been positioned in the kink of the right external iliac artery, which
limits the ﬂow considerably. This patient later developed a right
limb graft occlusion.
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clusive limb lesion (an asymptomatic and documented
progressive thrombus of a graft limb) that was found on
routine postoperative imaging. They were successfully
treated with oral anticoagulation (acenocoumarol, n ¼ 1)
or surgically with relining of the former endograft limb
with a new Endurant endograft limb (n ¼ 1). These
patients were not included in the occlusion group but are
mentioned here as part of a possible spectrum of throm-
botic complications that could eventually lead to occlusion
if left untreated. In addition, one patient developed a symp-
tomatic stenosis after an occlusion of the contralateral
endograft limb, also prompting intervention.
Clinical presentation of occlusion. Presenting symp-
toms in 10 of the 20 patients with occlusion were acute
ischemia with numbness, sensory loss, but no rest pain in
three (15%), with an occlusion (Rutherford IIa) or acute
ischemia with rest pain or loss of motor function, or
both, in seven (35%; Rutherford IIb). The remaining 10
(50%) presented with claudication without rest pain (Ruth-
erford stage I-III) and were diagnosed during regular
follow-up (Table IV).
Detailed analysis of patients with occlusion. Occlu-
sion occurred in two AUIs (5.2% of all AUIs) and in 18
bifurcated stent grafts (3.9% of all bifurcated endografts).
Total occlusion of the endograft occurred in three
patients. In patients with only one affected limb, no
signiﬁcant difference could be found regarding the side
of occlusion, with 10 of 17 (58%) noted as contralateral
limb occlusions.
Median time between primary EVAR and detection of
the occlusion was 1 month (range, 0-15 months), with55% (11 of 20) occurring within the ﬁrst 60 postoperative
days (early occlusions), 35% (7 of 20) between 2 and 12
months, and 10% at >12 months after EVAR.
All patients were prescribed a platelet aggregation
inhibitor (n ¼ 16) or a vitamin K antagonist (n ¼ 4) at
the time of occlusion.
In 12 patients (60%), a technical error was considered to
be the cause of the occlusion, including extreme oversizing,
positioning of the graft in a kink of the iliac vessel limiting
outﬂow considerably (Fig 3), performance of the comple-
tion angiogram without removing the stiff guidewire, or
an overlooked indication for percutaneous transluminal
angioplasty/stenting, both within the endograft limb or
resulting from the presence of a hemodynamically signiﬁcant
stenosis of ﬂow-limiting dissection in the external iliac artery
during the initial procedure. No technical cause for the
obstruction was found in the other eight (40%). An outﬂow
problemwas identiﬁed in two of these patients, and two pre-
sentedwith very challenging anatomy, with severe tortuosity
of the iliac arteries or a narrow aortic bifurcation, which
might have been the cause for the occlusion. For the other
six patients, the occlusion remained unexplained.
Overall, there was a violation of the instructions for use
in six of 20 (30%) patients. Oversizing was considered
Table V. Anatomic and operative details of patients with occlusion
Pt
Days to
occlusion
Occluded
side
History of
PAD
Severe iliac
tortuosity Within IFU
Extension
to IEA Open IIA
Iliac component
diameter
Iliac
oversizing, %
Stiff wire
removed
1 1 Left (I) Yes No No Yes No 24 14 Yes
2 2 Left (C) No No Yes No Yes 13 44 Yes
3 3 Right (C) No Yes Yes No Yes 13 8 Yes
4 12 Right (I) Yes No Yes No No 16 60 Yes
5 20 Right (C) Yes No Yes No Yes 10 11 Yes
6 21 Right (I) No No Yes Yes No 13 30 Yes
7 28 Right (C) No Yes No Yes No 10 43 No
8 32 Right (I) Yes No No Yes Yes 24 5 No
9 34 AUI Yes Yes Yes No Yes 13 18 Yes
10 40 Left (I) No No Yes Yes No 16 14 Yes
11 42 Right (C) No No Yes No No 13 30 Yes
12 62 Left (C) No Yes No Yes No 13 30 Yes
13 121 Left (C) No No Yes Yes No 13 44 Yes
14 183 Body No No Yes No Yes R:13, L:10 18/10 Yes
15 186 Left (I) No No Yes No Yes 24 33 Yes
16 275 Right (C) No No Yes No Yes 10 10 Yes
17 341 Right (I) No No Yes No Yes 16 33 Yes
18 241 Right (C) No Yes No Yes No 16 33 Yes
19 457 Right (C) No Yes Yes No Yes 24 9 Yes
20 458 AUI No No No No Yes 20 20 Yes
AUI, Aortouniiliac; C, contralateral; I, ipsilateral; IEA, external iliac artery; IFU, instructions for use; IIA, internal iliac artery; L, left; PAD, peripheral arterial
disease; R, right.
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(>35%) in four patients. Nine patients had one or more
risk factors for occlusion, including three with a known
malignancy at time of occlusion and seven with a medical
history of stroke or cardiac arrhythmia. Details on the indi-
vidual patients with endograft occlusion are presented in
Table V and Fig 4.
In four of 20 patients (20%), an in-graft stenosis was
reported on follow-up imaging before the occlusion, which
might have been a risk factor for the future occlusion. No
treatment was started at the time of these investigations
because of absence of clinical symptoms and absence of
>50% luminal stenosis. The occlusion in another four
patients was already present on the ﬁrst follow-up imaging.
Treatment. Different treatment modalities were used
depending on the clinical presentation, the patient’s phys-
ical status, and the underlying cause of occlusion. Open
surgical treatment was performed in 15 patients (75%)
with occlusion, comprising embolectomy (n ¼ 4), graft
extension (n ¼ 1), femorofemoral crossover bypass
(n ¼ 5), axillofemoral bypass (n ¼ 2), and embolectomy
with stent placement (n ¼ 3). In four of these patients,
an initial attempt was made to perform catheter-based
thrombolysis but this was unsuccessful.
Percutaneous treatment was successfully performed in
ﬁve (25%), including thrombolysis with (n ¼ 4) or without
(n ¼ 1) additional percutaneous transluminal angioplasty/
stent placement (Table VI).
Treatment results. Successful revascularization was
achieved in 17 of 20 occlusions (85%). The remaining
three patients died as a result of ischemia-related (n ¼ 2)
or intraoperative bleeding (n ¼ 1) complications, as
described previously.After successful revascularization reocclusion occurred
in ﬁve of 17 patients (29.4%), including occlusion of a fem-
orofemoral crossover bypass (n ¼ 2) and reocclusion after
thrombolysis in combination with stent placement (n ¼ 2)
or after surgical embolectomy (n ¼ 1). Time to reocclusion
varied from 2 weeks to 7 months after the initial revascular-
ization. Reocclusion presented as acute ischemia in these
ﬁve patients, and invasive treatment was performed to
restore vascularization with a femorofemoral crossover
bypass (n ¼ 2), thrombolysis (n ¼ 1), or thrombectomy
and extension of the graft limb (n ¼ 1). Revascularization
failed in one patient, resulting in above-knee amputation.
DISCUSSION
In this cohort of 496 patients treated with an Endurant
endograft and monitored for a median of 1.7 years, 20
occlusions occurred (4.0%). Occlusion-related mortality
was 0.6% overall (3 of 496) and 15% (3 of 20) in the occlu-
sion group.
EVAR has been increasingly used to treat AAAs. Early
advantages of EVAR over open surgical repair are well
known,30-33 and new-generation endografts have been
developed in recent years to broaden the treatment range.
The Endurant endoprosthesis, with a hydrophilic coating,
smaller delivery system, and increased ﬂexibility, was
specially designed to overcome complex aortoiliac anatomy.
With these expanding indications, it is important to assess
the occurrence of subsequent complications, such as stent
graft or access artery occlusion, and the need for secondary
interventions to obtain patency during follow-up.
Previous evaluations of the Endurant stent graft found
the incidence of graft-related occlusion varied from 1.3% to
3%.21-24 These occlusion rates are comparable to those in
Fig 4. Overview of time to occlusion and the probable cause of occlusion is shown for (A) early occlusion occurring
within the ﬁrst 60 postoperative days and (B) delayed occlusion. EVAR, Endovascular aneurysm repair.
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overlap of patients in these studies and ours.
Makaroun et al34 recently published the results from
the United States regulatory trial of the Endurant Stent
Graft System.34 They found an occlusion rate of 2.7% at
1 year, with all four cases occurring within the ﬁrst 60 days.
In a European multicenter study by Torsello et al21 of
45 patients treated with the Endurant stent graft, one graft
limb thrombosis (2.2%) was diagnosed at 30 days of
follow-up, which was successfully treated.21 No other
occlusions occurred during 1 year of follow-up. Troisiet al22 performed a single-center study to evaluate results
of the Endurant stent graft in 156 patients with a mean
follow-up of 9 months. The endograft occlusion rate was
1.9% (n ¼ 3), and all three patients were treated success-
fully. The rates of occlusion of these reports are, therefore,
comparable to the results of this study.
A wide range (0%-7.2%) of graft occlusions has been re-
ported in follow-up studies of other EVAR devices.2,4-25
The publication dates, institutional characteristics, follow-
up duration, and patient cohorts in these studies are very
heterogenic, which may explain the variability in occlusion
Table VI. Treatment
Variable No. (%)
Open surgery 15 (75)
Embolectomy 4 (20)
Graft extension 1 (5)
Femorofemoral crossover bypass 5 (25)
Axillofemoral bypass 2 (10)
Embolectomy with stent 3 (15)
Initial thrombolysis attempt 4
Percutaneous intervention 5 (25)
Thrombolysis/PTA with stent 4 (13.6)
Thrombolysis/PTA without stent 1 (4.5)
PTA, Percutaneous transluminal angioplasty.
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where institutional protocols are very similar, a signiﬁcant
difference was still found in the occlusion rates of the partici-
pating hospitals.
More than half of all occlusions in this study occurred
#2 months after EVAR, and 90% occurred within the ﬁrst
year. This observation is in agreement with previous publi-
cations2,5 and alerts to the importance of careful observa-
tion and patient information, especially during the ﬁrst
year after EVAR. In this study we used a review board to
come to a consensus on possible causes for limb occlusion.
This review board concluded that a technical error was
responsible for occlusion in 60% of all patients and in
73% of those with early occlusions. A more liberal intrao-
perative and early postoperative (re)intervention strategy
may reduce the occlusion rates and improve outcome.
Importantly, completion angiography should be performed
after removal of the stiff guidewire and the imaging thor-
oughly checked to assess for irregularities or stenosis.
This should also include rotational views in which the
angled and tortuous iliac arteries are perpendicularly visual-
ized. Direct pressure measurements at the sheaths after all
endovascular material is removed may also aid in the iden-
tiﬁcation of any hemodynamic obstruction to ﬂow.
We observed a signiﬁcant proportion of patients with
a history of peripheral arterial disease, with poor outﬂow
vessels, and very challenging iliac anatomy, possibly
increasing the risk of occlusion. Facilitating iliac access
with improved delivery systems may have the perverse
effect of increasing the risk of occlusive complications.
Although we cannot objectively demonstrate that these
factors increase risk signiﬁcantly, treatment of patients
with major obstructive disease and very unfavorable
anatomy undoubtedly increases the chance of endograft
occlusion.
Occlusion in ﬁve patients occurred without any sugges-
tive cause. Aneurysm remodeling might play an important
role in patients with delayed occlusion, but this remains
unproven. Circumferential thrombus deposition, occurring
in >20% of patients, also may increase risk.
Mestres et al35 found that the presence of intragraft
mural thrombus signiﬁcantly increased the risk of endograft
occlusion. However, the study by Wegener et al36 foundno association with graft occlusion, and the thrombotic
deposits in 15% disappeared completely during follow-up,
without speciﬁc therapy. It is known from clinical practice
that some patients are prone to thrombosis of vascular
conduits, a problem seldom investigated. This may be
a result of a genetically determined variability to foreign
body response or antiplatelet resistance, or as a result of
sheer stress, and may correspond to patients without
obvious underlying causes for thrombosis and with recur-
rent events. Nine patients in the occlusion group presented
with one or more possible risk factors for thrombosis in
their medical history, including malignancy, cardiac
arrhythmias, or cerebrovascular accident or transient
ischemic attack, that might have contributed to the devel-
opment of the occlusion.
Clinical presentation of occlusion was acute in only
50% of patients, with the remaining presenting with claudi-
cation. Other studies report higher percentages of acute
presentation.5,37 The risk was naturally higher in patients
with acute limb ischemia, where all of the deaths occurred,
and the clinical consequences of this complication should
not be underestimated.
All patients in our study required an intervention to re-
establish ﬂow to the ischemic extremity, and open surgery
was preferred for most patients. Although initial revascular-
ization was successful in >80%, we observed a reocclusion
rate of 29.4%, all of which required secondary intervention.
We do not have a clear explanation for this high reocclu-
sion rate, although an outﬂow obstruction may have
been a contributing factor in at least three patients.
Numerous causes and predictive factors for graft
obstruction have been suggested in the literature, such as
extension of the graft limb to the external iliac artery,2,4
smaller limb diameter,2 AUI endograft,35 younger age,5
the presence of thrombus in the native aorta,26 or type of
device.1,4,10,37,38 In the present study, we evaluated sex
and older age (>65 years) and found no signiﬁcant associ-
ation with occurrence of occlusion. Also, the type of device
(bifurcated vs AUI endograft) did not inﬂuence the
outcome.
One of the limitations of this study is its retrospective
design. Also, we could not obtain detailed anatomic infor-
mation for patients without occlusions, and analysis of risk
factors for occlusion is limited. Our data suggest, however,
that additional factors other than the stent graft material
may play an important part in the occlusion rates, particu-
larly on the patient selection criteria or institutional policies
on additional intraoperative or postoperative preventive
intervention.
CONCLUSIONS
Endograft occlusion after EVAR is an important
complication that persists with newer-generation devices.
In this study, occlusion occurred in 4.0% of patients treated
with the Endurant stent graft during a median follow-up of
1.7 years. The risk of occlusion is higher within the ﬁrst
2 months after EVAR, rarely occurring after 1 year. The
estimated freedom from occlusion at 30 days, 1 year, and
JOURNAL OF VASCULAR SURGERY
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nical justiﬁcation for occlusion could be found for 60% of
patients. These correspond to most early events and could
potentially be prevented by adopting a more aggressive
strategy for identiﬁcation and treatment of intraoperative
and early postoperative signs of kinking, stenosis, or irreg-
ularities. Still, the reason for occlusion in a number of
patients is unexplained. Institutional practice and case-
mix may inﬂuence occlusion rates signiﬁcantly.
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congratulate you on a very important paper. I think the topic is
very pertinent now that we are exploring using lower-proﬁle stents
for infrarenal aneurysms. A little bit more about your method-
ology. Can you tell us whether you analyzed other thromboem-
bolic events in addition to the classic end point of limb
occlusion? It would be ideal for future comparisons with other
devices to have more granularity on thrombus formation and
changes in the ankle-brachial index. Also, have you evaluated
changes such as nonocclusive thrombus formation in the limbs
using repeated computed tomography (CT) scans?
Dr Laura van Zeggeren. Thank you. In this study, we
focused on patients who had a symptomatic obstruction, deﬁned
as clinical symptoms of limb ischemia in combination with
a complete occlusion of the endograft (body or a limb) or
stenosis. In the majority of patients, we found a complete occlu-
sion, but there were also patients who presented with claudica-
tion and who had a signiﬁcant stenosis or thrombus of one of
the graft limbs. Ankle-brachial index data were not available in
this study. We did not analyze CT scans of asymptomatic
patients for the presence of thrombus or stenosis in the current
study.
Dr Ian Loftus (London, UK). Can you tell us any more about
the native anatomy here as to whether these were predictable or
not? These are very high limb occlusion rates. If you included
the asymptomatic obstructions, this must be closer to 8%. So is
this a problem with the device or is it because the low proﬁle device
is pushing the boundaries of what you can treat?
Dr van Zeggeren. This is a very interesting question. In the
present study we only evaluated patients with a symptomatic
obstruction so we cannot say anything about the asymptomatic
obstruction rate. Now that we have found an endograft obstruc-
tion rate of 4.0%, it is indeed essential to further investigate
whether there is a relationship between complex anatomy and graft
obstruction and to identify other possible risk factors in order to
get a better understanding of the pathophysiology of graft obstruc-
tion and answer your last question.
Dr John Ricotta (Washington, DC). Did the patients who
obstructed have what looked like difﬁcult anatomy when you
looked at their preoperative CT scans?Dr van Zeggeren: We did look at the preoperative scans and
there certainly were patients with difﬁcult anatomy, but in this
stage of the study, we cannot statistically evaluate whether this is
a risk factor for obstruction because we did not evaluate CT scans
of patients without symptomatic obstructions. As mentioned
earlier, it is worthwhiledand we are aboutdto further investigate
this in order to extract predictive factors for obstruction and learn
more about patients and endografts at risk.
Dr Jean-Paul de Vries (Nieuwegein, The Netherlands). I am
the senior author of the manuscript. Approximately 30% of the
patients were treated outside the instructions for use, and this
was mainly because of the proximal infrarenal necks, with heavy
angulation, large diameter, or short necks. Concerning the access
arteries, perhaps a small percentage of the patients were outside
the instructions for use.
Dr Gale Tang (Seattle, Wash). Speaking to that, did you look
at how many of these devices were extended into the external iliac,
or were these patients with very small external iliac diameters?
Dr van Zeggeren. That is a good question, especially because
extension of the graft into the external iliac artery has been
described as risk factor for graft obstruction in the literature. In
a small percentage of patients in the obstruction group, there
was extension of the graft into the iliac artery. We did not have
data on the external iliac artery diameters of the whole population
or whether they were deployed in the external iliac artery and,
therefore, did not separately analyze this in the obstruction group.
However, we will more closely look at the iliac anatomy of the
patients in the obstruction group to get a better understanding
of possible risk factors that can be evaluated in the future.
Dr Edward Woo (Philadelphia, Pa). One other question:
You have a high majority of patients that you bailed out with
surgical methods. Were all of these patients attempted percutane-
ously ﬁrst; and if not, how come?
Dr van Zeggeren. Almost all of the patients who were treated
surgically were directly treated surgically. Four patients had ﬁrst an
endovascular attempt to treat the graft occlusion, but these were
not successful.
Dr Woo. Do you know why not?
Dr van Zeggeren. An attempt was made to start thromboly-
sis, but we could not pass the obstruction with guidewires.
